Dr. Traci Downs has over eighteen years of experience in functional neuroimaging and neuroscience with extensive work with functional magnetic resonance imaging (fMRI) and positron emission tomography (PET). Since 2005, she has been the president and Chief Operating Officer of Archinoetics where she achieved 400% growth in the first four years. From 2007 to 2011, she was the CEO of Fatigue Science, an Archinoetics spin-off company. Until 2011, she also served on the Board of Directors for the Hawaii Science & Technology Council.Previously, she has been a Program Manager of a research portfolio worth over $15M from government agencies, private industry, and non-profit organizations. She has authored or co-authored over 20 publications related to functional brain imaging and is exploring innovative ways of coupling emerging technologies with interactive computer interfaces. In 2006, she received the Pacific Business News "Forty under Forty" award for the best business leaders under the age of 40 in Hawaii an, in 2011, the Entrepreneur of the Year Award from the Hawaii Venture Capital Association.
Wade Beavers was a co-founder and CEO of DoApp Inc. and mRemedy where he lead the company to three successful product acquisitions. Beavers is currently President of Mobile for NEWSCYCLE Solutions, and also CEO of a new health start up uBody Inc. He has investments in technology solutions for wellness, agriculture, and commerce. Beavers and DoApp have been featured in Bloomberg, Vator News, MSNBC, ESPN Magazine, and in the New York Times best selling book, “The Entrepreneur Equation” by Carol Roth.
Julie A. Henry is an Enterprise IP Contract Manager in Department of Business Development, Mayo Clinic Ventures at Mayo Clinic in Rochester, Minnesota. Her responsibilities involve collaborating with internal and external customers as a resource to manage unique and complex intellectual property related contractual issues across the entire Mayo enterprise. Additionally, is involved in the evaluation, patent strategy and out-licensing of a portfolio of Mayo Clinic inventions. Ms. Henry has been with Mayo Clinic for over twenty-five years. She has had experience in all facets of the commercialization process including drafting, negotiating and management of agreements. She has given presentations relating to licensing technologies as well as educating staff concerning intellectual property protection and commercialization. Before taking her position in Mayo Clinic Ventures, Ms. Henry was a Research Technician in the Peptide Synthesis Protein Sequencing Core Facility in Mayo Clinic’s Biochemistry and Molecular Biology Department. Ms. Henry received her B.A. from St. Cloud State University in St. Cloud, Minnesota and her Master of Business Administration from University of St. Thomas in Minneapolis, Minnesota.
Christine Beech is the Executive Director of the Kabara Institute for Entrepreneurial Studies at Saint Mary’s University of Minnesota as well as an Assistant Professor of Business. Christine’s teaching, research and consulting experience are in the areas of strategic management, leadership development, contract management, succession planning, social entrepreneurship, and small business management. Prior to joining Saint Mary’s University, Christine worked in corporate entrepreneurship where she led the development of a multi-million dollar business line for a global consulting firm before launching her own consulting business in the Washington, D.C. area. Christine also served in the military, learning German and Russian and traveling the world as an intelligence officer. She holds a Master’s Degree in Management and is a Doctoral Candidate at UMUC writing her dissertation on Social Entrepreneurship in Faith-based Nonprofits.
Dr. Perry Hackett is a co-founder of Recombinetics and serves as Chair of its Scientific Advisory Board. He is co-founder of gene therapy company, Discovery Genomics, where he previously served as Chief Scientific Officer and Chairman. He is also a professor and research scientist in the University of Minnesota’s department of Genetics, Cell Biology and Development and co-founder of the Center for Genome Engineering. Hackett has a degree in Physics from Stanford University, a PhD in Biophysics and Genetics from the University of Colorado, and did postdoctoral training at the Max Planck Institute for Cell Biology in Germany and at the University of California in San Francisco.
Dr. J. Fernando Bazan was appointed Chief Technology Officer when he joined BioTechne on August 1, 2013. Following training at Stanford, Berkeley, and UCSF in biochemistry and biophysics, he led very active groups in biotherapeutics discovery as a senior scientist at DNAX Research Institute (now Merck Research Labs) and at Genentech (Roche). He also served as Chief Scientific Officer at NeuroScience, a neuroimmunology diagnostics startup. Dr. Bazan holds an adjunct faculty appointment in the Dept. of Pharmacology at the University of Minnesota School of Medicine.